Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT TrialsMeredith M. Regan, Richard D. Gelber, Marco Colleoni et al.|Journal of Clinical Oncology|2016Cited by 184
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)Thomas Bachelot, A Wroński, Eva Ciruelos et al.|Annals of Oncology|2019Cited by 117
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor–Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00Marco Colleoni, Aron Goldhirsch, Kathryn P. Gray et al.|Journal of Clinical Oncology|2016Cited by 77